Assist. Prof. Dr. Amir Abaas Momtazi-Borojeni | Biotechnology | Best Researcher Award

Faculty Member from Neyshabur university of medical sciences, Iran

Dr. Amir Abbas Momtazi-Borojeni is an Assistant Professor of Medical Biotechnology at Neyshabur University of Medical Sciences in Iran. Born on September 17, 1985, in Isfahan, Iran, he has established a distinguished career in medical biotechnology, focusing on nanomedicine, immunotherapy, and phytomedicine. With over 160 publications and more than 7,000 citations, his research has significantly contributed to the fields of cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies and nanoliposomal drug delivery systems has been recognized internationally. Dr. Momtazi-Borojeni’s interdisciplinary approach integrates molecular biology, pharmacology, and bioinformatics, reflecting his commitment to advancing medical science through innovative research.

Professional Profile​

• Scopus Profile
• ORCID Profile
• Google Scholar

Education

Dr. Momtazi-Borojeni’s academic journey began with a BSc in Biology from Isfahan University (2004–2008), followed by an MSc in Microbial Biotechnology from the same institution (2008–2010). He then pursued a Ph.D. in Medical Biotechnology at Mashhad University of Medical Sciences (2013–2019), where his research focused on developing nanoliposome-based vaccines targeting PCSK9 for lipid-lowering and anti-atherosclerotic effects. His doctoral work combined immunology, nanotechnology, and cardiovascular research, laying the foundation for his future contributions to medical biotechnology.​

Professional Experience

Dr. Momtazi-Borojeni has held various research and academic positions, including roles as a genomics lab expert at the Biotechnology Research Institute in Esfahan and as a part-time researcher at the Pharmaceutical Sciences Research Center of Isfahan University of Medical Sciences. He has also taught courses in cellular and molecular biology, genetic engineering, and bioinformatics at Isfahan University and Islamic Azad University, Neyshabur branch. Currently, he serves as an Assistant Professor at Neyshabur University of Medical Sciences, where he continues to advance research in medical biotechnology.​

Research Interests

Dr. Momtazi-Borojeni’s research interests encompass nanomedicine, immunotherapy, and phytomedicine, with a particular focus on developing innovative treatments for cardiovascular and metabolic diseases. His work on PCSK9-targeted therapies, including vaccine development and siRNA delivery systems, aims to provide alternative strategies for managing hypercholesterolemia and atherosclerosis. Additionally, he explores the therapeutic potential of natural compounds and bioinformatics approaches to identify novel drug targets and understand disease mechanisms.​

Research Skills

Dr. Momtazi-Borojeni possesses a diverse skill set that includes expertise in nanotechnology-based drug delivery, molecular biology techniques, immunological assays, and bioinformatics analysis. His proficiency in designing and characterizing nanoliposomes, conducting in vivo studies, and analyzing gene expression profiles enables him to undertake complex research projects that bridge multiple disciplines. His collaborative work with international researchers further demonstrates his ability to contribute to multidisciplinary teams and advance scientific knowledge.​

Awards and Honors

While specific awards and honors are not detailed in the provided information, Dr. Momtazi-Borojeni’s extensive publication record and citation metrics reflect his significant impact on the field of medical biotechnology. His research has been published in reputable journals, and his contributions to the development of PCSK9-targeted therapies have garnered international recognition. His active participation in scientific communities and collaborations with researchers worldwide underscore his commitment to advancing medical science.​

Conclusion

Dr. Amir Abbas Momtazi-Borojeni’s extensive research in medical biotechnology, particularly in the areas of nanomedicine and immunotherapy, positions him as a strong candidate for the Best Researcher Award. His innovative approaches to treating cardiovascular and metabolic diseases, combined with his interdisciplinary expertise and collaborative spirit, have significantly advanced the field. While specific awards and honors are not listed, his prolific publication record and international collaborations attest to his contributions to medical science. Continued support for his research endeavors will likely yield further breakthroughs in therapeutic strategies and enhance our understanding of complex diseases.​